North America & Europe Age-related Macular Degeneration Therapeutics Market to Benefit from Increasing Geriatric Population

 

North America & Europe Age-related Macular Degeneration Therapeutics Market

Age-related macular degeneration causes loss in the center of the field of vision. According to Bright Focus Foundation, around 11 million people in the U.S. have some form of age-related macular degeneration and the number is expected to double to nearly 22 million by 2050. Such scenario is expected to aid in growth of the North America & Europe age-related macular degeneration therapeutics market.

Age-related macular degeneration is a common condition — it’s a leading cause of vision loss for people age 50 and older. According to the U.S. Census Bureau, the U.S. geriatric population is expected to reach 77 million by 2034. Thus, increasing geriatric population is a major contributor in growth of the North America & Europe age-related macular degeneration therapeutics market.

Dry age-related macular degeneration is a common eye disorder among people over 50. It causes blurred or reduced central vision, due to thinning of the macula (MAK-u-luh). Dry age-related macular degeneration is a more common condition for which there is currently no approved treatment. In April 2021, LumiThera Inc., a major player in the North America & Europe age-related macular degeneration therapeutics market and a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and disease, announced positive findings in its LIGHTSITE II, multi-center clinical trial in dry age-related macular degeneration patients. 

R&D in stem cell therapy and long-acting PASylated nomacopan is expected to aid in growth of the North America & Europe age-related macular degeneration therapeutics market. Age-related macular degeneration results from the death of a type of eye cells called retinal pigmented epithelial (RPE) cells and causes vision loss. Stem cell therapy can be used to create healthy RPE cells from induced pluripotent stem cells --stem cells that are generated from each patient's blood cells -- to replace the damaged cells in the eye and restore vision. Akari Therapeutics, Plc, a late-stage biopharmaceutical company is working on LTB4-VEGF axis in the development of sight-threatening retinal inflammation. In a recently published study, entitled "Immune-Mediated Retinal Vasculitis in Posterior Uveitis and Experimental Models: The Leukotriene (LT)B4-VEGF Axis," the company highlighted the role LTB4 (a leukotriene involved in inflammation) plays in the induction of vascular endothelial growth factor (VEGF) damage and retinal inflammation in the eye.

Comments

Post a Comment

Popular posts from this blog

Astrum Has Expanded Its Presence In India Infrared Thermometer Market

Image
  The Infrared Thermometer market is witnessing the fastest growth in the Asia Pacific region and this can be accredited to the growing aging population in the region which is driving demand for healthcare services. Japan has the highest growing aging population in the country. According to the Statistics Bureau, Ministry of Internal Affairs and Communications, in 2019, the aged population (65 years old and over) was 35.89 million, constituting 28.4 percent of the total population (i.e., 1 in every 4 persons) and marking a record high in Japan. The rise in prevalence of infectious disease and increase in the demand for the product for newborns as children cannot hold the contact thermometer is playing a key role in the overall development of the infrared thermometer market . According to the World Health Organization, HIV, tuberculosis, malaria, neglected tropical diseases, and viral hepatitis affects billions of people around the world and causes more than 4 million deaths each year
Read more

The Global Meningococcal Vaccines Market Continues To Grow Owing To the Demand from Healthcare Care Sectors across the World to Prevent the Spread of the Diseases Especially In Children

Image
  Meningococcal vaccines prevent the contraction of meningococcal diseases, including meningitis caused by the bacteria called meningococcus aureus. An outbreak of meningococcal disease is usually followed by an onset of meningitis. Meningococcal meningitis can cause permanent damage to the brain or spinal cord in as little as 10 days, depending on the degree of infection and the natural immunity of the person. Since meningitis is usually associated with a fever and signs and symptoms of a serious illness, many parents prefer not to use the traditional treatments for their children such as meningitis or oral antibiotics. Instead, they often resort to various forms of therapeutic interventions that may even improve their chances of developing a positive outcome. Meningococcal vaccines are now available for meningococcal meningitis, as well as for men who have had other prior bouts of meningitis. Some vaccines used for these purposes are PPSV, Rallo, and Q fever type 1. These vaccines
Read more

Increasing Geriatric Population Is Driving the Growth of the Sexual Health Market

Image
       Sexual health is an important part of a person’s physical and mental health. According to the World Health Organization (WHO), sexual health requires a respectful and positive approach to sexual relationships and sexuality, as well as the possibility of having pleasurable and safe sexual experiences, free of coercion, violence, and discrimination. Sexual health leads to a healthy sex life without any sexually transmitted diseases, and to take preventive measures to avoid sexually transmitted infections. The elderly population (geriatric population) often suffer from one or more sexual disorders, such as premature (early) ejaculation, erectile dysfunctions, dyspareunia, and hypoactive sexual desire disorder, among others. Thus, with the increasing geriatric population worldwide, the prevalence/incidence of sexual disorders is also increasing, driving the growth of the sexual health market . According to WHO, the world's population aged 60 years and older is expected to tota
Read more